FDA Clears Phase 1/2 Clinical Trial for Spinogenix’s ALS Treatment SPG302
Spinogenix Announces FDA Clearance of IND Application Novel Therapy for the Treatment of ALS
World-first MND drug trial offers hope to those living with the disorder
FDA OKs Phase 1/2 clinical trial of small molecule SPG302 in ALS
FDA clears investigational new drug application for clinical trial of ALS pill
Synapse-Generating Small Molecule for ALS Receives Nod from FDA for Clinical Trial
FDA grants IND clearance for Spinogenix’s ALS treatment trial
Breakthrough synapse-regenerating ALS pill moves to phase 2 human trials
Spinogenix’s Daily Pill SPG302 Receives FDA IND Nod for ALS Treatment
ALS ONE Research Symposium – Presentation by Peter Vanderklish, PhD of Spinogenix
